Annonce • Mar 18
Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2025 Results on Mar 29, 2026 Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2025 results at 9:30 AM, China Standard Time on Mar 29, 2026 Annonce • Feb 21
Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy The board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 12, 2026, Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, the Group's innovative drug, has been approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced non-small cell lung cancer ("NSCLC") whose tumours have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Annonce • Jan 08
Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of the Fifth Indication of Ameile (Aumolertinib Mesylate Tablets) Was Granted by the National Medical Products Administration The board of directors of Hansoh Pharmaceutical Group Company Limited announced that, the Group's innovative drug Ameile (Aumolertinib Mesylate Tablets) has been granted drug registration approval by the National Medical Products Administration (" NMPA") of China, approving the addition of an indication: Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. This is the fifth indication of Ameile which has been approved. Annonce • Aug 21
Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion. Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 108,000,000
Price\Range: HKD 36.3
Transaction Features: Subsequent Direct Listing Annonce • Aug 07
Hansoh Pharmaceutical Group Company Limited to Report First Half, 2025 Results on Aug 18, 2025 Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2025 results on Aug 18, 2025 Annonce • Jun 05
Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for Marketing The board of directors of Hansoh Pharmaceutical Group Company Limited announced that, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®?), the Group's innovative drug, has been approved by the Medicines and Healthcare Products Regulatory Agency ("MHRA") in the UK for marketing. Aumseqa®? as monotherapy is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with activating epidermal growth factor receptor (" EGFR") mutations, and the treatment of adult patients with locally Advanced or metastatic EGFR T790M mutation-positive NSCLC. Annonce • May 31
Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products Administration The board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on May 29, 2025, the third biologics license application ("BLA") of XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the "Product") has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of generalized myasthenia gravis (gMG) in adult patients. Annonce • Apr 17
National Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093 for Injection Hansoh Pharmaceutical Group Company Limited announced that, on April 17, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (" NMPA") of China, with the proposed indication for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, progressed or recurred following platinum-based chemotherapy. Annonce • Apr 15
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for Hs-10529 Tablets The board of directors of Hansoh Pharmaceutical Group Company Limited announced that, HS-10529 tablets, a Small Molecule Category I Innovative Drug targeting KRAS G12D self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer, etc.) with KRAS G12D mutations. Annonce • Mar 21
Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2024, Payable on July 25, 2025 Hansoh Pharmaceutical Group Company Limited proposed final ordinary dividend of HKD 0.1353 per share for the year ended December 31, 2024. Ex-dividend date: July 3, 2025. Record date: July 9, 2025. Payment date: July 25, 2025. Annonce • Mar 20
TiumBio Co., Ltd.'s Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development TiumBio Co. Ltd. announced that its partner, Hansoh Pharma, has expanded the clinical indications of merigolix (Hansoh's code: HS-10518), an oral gonadotropin-releasing hormone receptor antagonist. Orally administered merigolix may be important in the control of premature endogenous LH surge and in reducing the cycle cancellation rate, with an improvement of pregnancy rate per cycle. Currently, in COS regimens, gonadotropin-re releasing hormone (GnRH) products are only available in injectable form, which caused the pain and relatively high cost. Meanwhile, merigolix is an oral GnRH receptor antagonist being developed for the treatment of endometriosis,uterine fibroids, and ART. TiumBio entered into a licensing agreement with Hansoh Pharma for merigolix for up to $170 million plus tiered royalties upon net sales. Under the terms of the agreement, Hansoh Pharma obtained exclusive rights to develop and commercialize merigolix in Greater China. Annonce • Mar 10
Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2024 Results on Mar 21, 2025 Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2024 results on Mar 21, 2025 Annonce • Mar 05
Hansoh Pharmaceutical Group Company Limited Announces Acceptance of Second Biologics License Application by the National Medical Products Administration The board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on March 4, 2025, the second Biologics License Application (BLA) of XINYUE (Inebilizumab Injection) has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of immunoglobulin G4-related disease (IgG4-RD). On February 8, 2025, this indication has been included in the Priority Review and Approval Procedure by the NMPA. Inebilizumab is a targeted CD19 B cell-depleting antibody. On May 24, 2019, the Group entered into a license agreement with Viela Bio (Viela Bio was acquired by Horizon Therapeutics in 2021, which was acquired by Amgen in 2023), and has been granted an exclusive license to develop and commercialize the Product in China's mainland, Hong Kong and Macao. On March 14, 2022, the Product was approved to be launched in China by NMPA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In January 2023, the Product was included in the National Reimbursement Drug List for the first time, and this inclusion was successfully renewed in November 2024. Annonce • Feb 10
Hansoh Pharmaceutical Group Company Limited Announces New Indication of Xin Yue (Inebilizumab Injection) Included in Priority Review and Approval Procedure by the National Medical Products Administration The board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 8, 2025, based on the positive results from the global pivotal Phase III MITIGATE trial on XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the Product), the new indication of the treatment of immunoglobulin G4-related disease (IgG4-RD) of the Product has been included in the Priority Review and Approval Procedure by the National Medical Products Administration (the NMPA). Annonce • Jan 24
Hansoh Pharmaceutical Group Company Limited Announces Changes to Company Secretary The board of directors of Hansoh Pharmaceutical Group Company Limited announced that, with effect from January 24, 2025, due to personal work arrangement, Ms. Tam Sze Wai Sara has tendered her resignation as a joint company secretary of the Company and ceased to be an authorized representative of the Company under Rule 3.05 of the Rule Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the process agent of the Company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent"). Following the resignation of Ms. Tam, the Board announces that Ms. Wong Yuen Ki (" Ms. Wong") has been appointed as the joint company secretary with effect from January 24, 2025. Ms. Wong is a senior manager of corporate services of Tricor Services Limited. Ms. Wong possesses more than 10 years of experience in the company secretarial field. Ms. Wong is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Wong holds a degree of Bachelor of Business Administration in Corporate Administration and degree of Master of Corporate Governance from Hong Kong Metropolitan University. Ms. Wong possesses the academic or professional qualifications of a company secretary as required under Rule 3.28 of the Listing Rules. With effect from January 24, 2025, the joint company secretaries of the Company are Ms. Zhong Shengli and Ms. Wong. Annonce • Nov 27
Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products Administration Hansoh Pharmaceutical Group Company Limited announced that, the fifth New Drug Application ("NDA") of the Group's innovative drug Ameile (A Mei Le ®?) (Aumolertinib Mesilate Tablets) has been accepted by the National Medical Products Administration of China ("NMPA"). The indication is that Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. . Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive. In July 2024, the NDA of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations was accepted by the NMPA. In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA. Annonce • Nov 01
Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093 The board of directors of Hansoh Pharmaceutical Group Company Limited announced that on November 1, 2024, the Group's self-developed B7-H3-targeted antibody-drug conjugate (‘ADC’) HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (‘NMPA’) of China, with the proposed indication being extensive stage small cell lung cancer (‘ES-SCLC’) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy). Annonce • Oct 22
Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC The board of directors of Hansoh Pharmaceutical Group Company Limited announced that Phase III registrational trial AENEAS2 evaluating Ameile in combination with chemotherapy as first line therapy for patients with locally advanced (Stage IIIB~IIIC) or metastatic (Stage IV) epidermal growth factor receptor mutated non-small cell lung cancer met its primary endpoint of progression-free survival .AMEILE combined with chemotherapy demonstrated statistically significant and clinically meaningful improvement in PFS in patients with EGFR mutated advanced lung cancer. Detailed results of the study will be presented at upcoming medical conference and will be submitted to regulatory authority. Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy, and was also successfully renewed in the 2022 National Reimbursement Drug List ("NRDL") in January 2023. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive, and has been included in the 2022 NRDL in January 2023. In July 2024, the New Drug Application ("NDA") of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations was accepted by the National Medical Products Administration (" NMPA "). In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA. Annonce • Aug 27
Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024 Hansoh Pharmaceutical Group Company Limited announced an interim dividend of HKD 0.201 per share for the six months ended June 30, 2024. Ex-dividend date is 20 September 2024. Record date is 25 September 2024. Payment date is 30 October 2024. Annonce • Aug 15
Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024 Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2024 results on Aug 27, 2024 Annonce • Jul 20
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China The board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ameile" (A Mei Le ®?) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 L858R mutations, was accepted by the National Medical Products Administration of the People's Republic of China. Ameile is a category 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co. Ltd. ("J Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), a subsidiary of the Company. The said application will be the third indication of Ameile. Annonce • May 01
Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024 Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024, at 10:00 China Standard Time. Location: 10/F United Centre, 95 Queensway Admiralty Hong Kong Agenda: To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended December 31, 2023; to approve the payment of a final dividend for the year ended December 31, 2023; to re-elect Dr. Lyu Aifeng as executive director; to re-elect Mr. Lin Guoqiang as independent non-executive director; to authorize the board of directors to fix the respective directors' remuneration; to re-appoint Ernst & Young as auditors and to authorize the board of directors to fix their remuneration; and to transact other business. Annonce • Apr 30
Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 Hansoh Pharmaceutical Group Company Limited announced that, with effect from April 29, 2024, Ms. Li Yan Wing Rita (Ms. Li) has tendered her resignation as a joint company secretary of the company and ceased to be an authorized representative of the company (the Authorized Representative) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the process agent of the company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance. Following the resignation of Ms. Li, the board announced that Ms. Tam Sze Wai Sara (Ms. Tam) has been appointed as a joint company secretary with effect from April 29, 2024. Ms. Tam is currently a manager of Corporate Services of Tricor Services Limited. She has over 10 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Tam is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Following the resignation of Ms. Li, she has also ceased to be an Authorized Representative and the Process Agent with effect from April 29, 2024. The Board announced that Ms. Tam, the newly appointed joint company secretary, has been appointed as an Authorized Representative and the Process Agent with effect from April 29, 2024. Annonce • Apr 03
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS- 10504 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced non-small cell lung cancer. The specific indication will be determined after the completion of clinical research. Annonce • Mar 15
Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 Annonce • Jan 17
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10509 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of schizophrenia. The specific indication will be determined after the completion of clinical research. Annonce • Nov 11
Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10511 tablets", a Category 1 innovative drug self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Jiangsu Hansoh Pharmaceutical Group Company Limited ("Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of hypertrophic cardiomyopathy (HCM). The specific indication will be determined after the completion of clinical research. Annonce • Oct 20
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections Hansoh Pharmaceutical Group Company Limited announced that "HS-20106 Injections" (the "Product"), a Category 1 therapeutic biological product has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China. The specific indication will be determined after the completion of clinical research. Annonce • Sep 26
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105" The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-20105", a Category 1 therapeutic biological product self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Changzhou Hansoh Pharmaceutical Company Limited ("Ch Chang Zhou Heng Bang Yao Ye You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumors. The specific indication will be determined after the completion of clinical research. Annonce • Sep 02
Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023 Hansoh Pharmaceutical Group Company Limited announced interim dividend of HKD 0.0707 per share for the six months ended June 30, 2023, payable on 28 September 2023. Record date to be 12 September 2023. Ex-dividend date to be 07 September 2023. Annonce • Aug 22
Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023 Hansoh Pharmaceutical Group Company Limited announced that they will report Q2, 2023 results on Aug 31, 2023 Annonce • Jul 23
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration The board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ibrexafungerp Tablets" has been accepted by the National Medical Products Administration, and it is intended to be used for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC). As disclosed in the announcement of the Company dated February 17, 2021, Hansoh (Shanghai) Healthtech Company Limited (Han Sen (Shang Hai) Jian Kang Ke Ji You Xian Gong Si) and Jiangsu Hansoh Pharmaceutical Group Company Limited (Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si), both wholly-owned subsidiaries of the Company, obtained an exclusive license from SCYNEXIS Inc. to research, develop and commercialize Ibrexafungerp in the People's Republic of China (including Hong Kong, Macau and Taiwan). Annonce • Jun 30
Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10518 Capsules" (license-in as TU2670, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the management of moderate to severe pain associated with endometriosis and management of heavy menstrual bleeding associated with uterine leiomyomas. Annonce • Jun 14
Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10516 Capsules" (license-in as NKT2152, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of renal cell carcinoma (RCC). Annonce • Jun 06
Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc Hansoh (Shanghai) Healthtech Company Limited obtained an exclusive license from Biotheus Inc. to develop and commercialize PM1080 within China (including Hong Kong, Macau and Taiwan). The board of directors (the "Board") of the Company announced that "HS-20117" (license-in as PM1080), a Category 1 innovative drug developed by the Group under the license from Biotheus, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumor. Annonce • May 06
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets" The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited announce that "HS-10506 tablets", a Category 1 innovative drug self- developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh BioMedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of depression and insomnia. The specific indication will be determined after the completion of clinical research. 
